Please use this identifier to cite or link to this item:
Full metadata record
|dc.identifier.citation||Lipworth W, Kerridge I (2013) China’s pharma scandal and the ethics of the global drug market, The Conversation||en_AU|
|dc.description.abstract||China is in the midst of conducting a series of corruption investigations of pharmaceutical
companies that have been operating in the country.
It all started with the investigation of officials from pharmaceutical company
GlaxoSmithKline, who were reportedly engaged in “bribery and corruption” in China. The
officials apparently used travel agencies to funnel illegal payments to doctors and
That was in July. In August, Associated Press reported French drug company Sanofi was
being investigated for bribing Chinese doctors in 2007.
And late last week, South China Morning Post reported that German pharmaceutical
conglomerate Bayer had joined the ranks of companies being investigated by the Chinese.
That report mentioned pharmaceutical companies Eli Lilly, Novo Nordisk, H Lundbeck,
AstraZeneca and UCB had also been contacted by Chinese investigators.
This wide-ranging, ongoing scandal highlights the many regulatory and ethical challenges of
globalised drug development||en_AU|
|dc.title||China’s pharma scandal and the ethics of the global drug market||en_AU|
|Appears in Collections:||Research Papers and Publications. Sydney Health Ethics|
This work is protected by Copyright. All rights reserved. Access to this work is provided for the purposes of personal research and study. Except where permitted under the Copyright Act 1968, this work must not be copied or communicated to others without the express permission of the copyright owner. Use the persistent URI in this record to enable others to access this work.
|TheConv-chinas-pharma-scandal-2013.pdf||236.67 kB||Adobe PDF|
Items in Sydney eScholarship Repository are protected by copyright, with all rights reserved, unless otherwise indicated.